In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's Shionogi Sues Sawai, Claiming Patent Violation For Antibiotic

This article was originally published in PharmAsia News

Executive Summary

Two Japanese pharmaceutical companies are headed for court over a generic version of a branded biotic drug. Shionogi has sued Sawai Pharmaceutical, saying it violated the plaintiff's patent for the crystallization technique used in making Flomox (cefcapene). Shionogi's cefcapene patent expired last October and Sawai began marketing a generic of it in May. Shionogi said its crystallization patent, however, remains effective through March 2011, and that Sawai's generic violates it. (Click here for more - a subscription may be required
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel